The relationship between serum NF-L levels and genetic markers and other AD biomarkers, including markers of inflammation and oxidative stress (both of which are increased in DS and associated with cognitive decline [19–22]), could also be explored in future research to refine prediction of cognitive decline and to stratify patients with Down syndrome according to dementia risk for clinical trials of potential treatments. Here, NEFL is linked to Down syndrome.